Cargando…

miRNA and antisense oligonucleotide-based α-synuclein targeting as disease-modifying therapeutics in Parkinson’s disease

α-synuclein is the synaptic protein majorly involved in neuronal dysfunction and death and it is well known for the last two decades as a hallmark of Parkinson’s disease. Alpha-synuclein is involved in neurodegeneration mediated through various neurotoxic pathways, majorly including autophagy or lys...

Descripción completa

Detalles Bibliográficos
Autores principales: Suvarna, Vasanti, Deshmukh, Kajal, Murahari, Manikanta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9728483/
https://www.ncbi.nlm.nih.gov/pubmed/36506536
http://dx.doi.org/10.3389/fphar.2022.1034072
_version_ 1784845266487083008
author Suvarna, Vasanti
Deshmukh, Kajal
Murahari, Manikanta
author_facet Suvarna, Vasanti
Deshmukh, Kajal
Murahari, Manikanta
author_sort Suvarna, Vasanti
collection PubMed
description α-synuclein is the synaptic protein majorly involved in neuronal dysfunction and death and it is well known for the last two decades as a hallmark of Parkinson’s disease. Alpha-synuclein is involved in neurodegeneration mediated through various neurotoxic pathways, majorly including autophagy or lysosomal dysregulation, mitochondrial disruption, synaptic dysfunction, and oxidative stress. Moreover, the alpha-synuclein aggregation has been associated with the development of several neurodegenerative conditions such as various forms of Parkinson’s disease. The recent discovery in oligonucleotide chemistry has developed potential alpha-synuclein targeting molecules for the treatment of neurodegenerative diseases. The present review article focuses on recent advances in the applications of oligonucleotides acting via alpha-synuclein targeting mechanisms and their implication in combating Parkinson’s disease. Moreover, the article emphasizes the potential of miRNAs, and antisense oligonucleotides and the challenges associated with their use in the therapeutical management of Parkinson’s disease.
format Online
Article
Text
id pubmed-9728483
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97284832022-12-08 miRNA and antisense oligonucleotide-based α-synuclein targeting as disease-modifying therapeutics in Parkinson’s disease Suvarna, Vasanti Deshmukh, Kajal Murahari, Manikanta Front Pharmacol Pharmacology α-synuclein is the synaptic protein majorly involved in neuronal dysfunction and death and it is well known for the last two decades as a hallmark of Parkinson’s disease. Alpha-synuclein is involved in neurodegeneration mediated through various neurotoxic pathways, majorly including autophagy or lysosomal dysregulation, mitochondrial disruption, synaptic dysfunction, and oxidative stress. Moreover, the alpha-synuclein aggregation has been associated with the development of several neurodegenerative conditions such as various forms of Parkinson’s disease. The recent discovery in oligonucleotide chemistry has developed potential alpha-synuclein targeting molecules for the treatment of neurodegenerative diseases. The present review article focuses on recent advances in the applications of oligonucleotides acting via alpha-synuclein targeting mechanisms and their implication in combating Parkinson’s disease. Moreover, the article emphasizes the potential of miRNAs, and antisense oligonucleotides and the challenges associated with their use in the therapeutical management of Parkinson’s disease. Frontiers Media S.A. 2022-11-15 /pmc/articles/PMC9728483/ /pubmed/36506536 http://dx.doi.org/10.3389/fphar.2022.1034072 Text en Copyright © 2022 Suvarna, Deshmukh and Murahari. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Suvarna, Vasanti
Deshmukh, Kajal
Murahari, Manikanta
miRNA and antisense oligonucleotide-based α-synuclein targeting as disease-modifying therapeutics in Parkinson’s disease
title miRNA and antisense oligonucleotide-based α-synuclein targeting as disease-modifying therapeutics in Parkinson’s disease
title_full miRNA and antisense oligonucleotide-based α-synuclein targeting as disease-modifying therapeutics in Parkinson’s disease
title_fullStr miRNA and antisense oligonucleotide-based α-synuclein targeting as disease-modifying therapeutics in Parkinson’s disease
title_full_unstemmed miRNA and antisense oligonucleotide-based α-synuclein targeting as disease-modifying therapeutics in Parkinson’s disease
title_short miRNA and antisense oligonucleotide-based α-synuclein targeting as disease-modifying therapeutics in Parkinson’s disease
title_sort mirna and antisense oligonucleotide-based α-synuclein targeting as disease-modifying therapeutics in parkinson’s disease
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9728483/
https://www.ncbi.nlm.nih.gov/pubmed/36506536
http://dx.doi.org/10.3389/fphar.2022.1034072
work_keys_str_mv AT suvarnavasanti mirnaandantisenseoligonucleotidebasedasynucleintargetingasdiseasemodifyingtherapeuticsinparkinsonsdisease
AT deshmukhkajal mirnaandantisenseoligonucleotidebasedasynucleintargetingasdiseasemodifyingtherapeuticsinparkinsonsdisease
AT muraharimanikanta mirnaandantisenseoligonucleotidebasedasynucleintargetingasdiseasemodifyingtherapeuticsinparkinsonsdisease